Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 nov. 2019 07h00 HE | Source: ProQR Therapeutics N.V.

ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123...
18 oct. 2019 08h20 HE | Source: ProQR Therapeutics N.V.

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of...
15 oct. 2019 23h17 HE | Source: ProQR Therapeutics N.V.

ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the...
15 oct. 2019 16h13 HE | Source: ProQR Therapeutics N.V.

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of...
15 oct. 2019 16h08 HE | Source: ProQR Therapeutics N.V.

ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
11 oct. 2019 06h02 HE | Source: ProQR Therapeutics N.V.

ProQR gibt positive Top-Line-Ergebnisse aus der Phase-1/2-Studie mit Sepofarsen bei LCA10-Patienten bekannt

Bericht spricht von schnellen, signifikanten und dauerhaften Verbesserungen der Sehkraft nach zwölf MonatenKonkordante Verbesserung bei den Messungen der wichtigsten sekundären ErgebnisseFür die...
11 oct. 2019 06h02 HE | Source: ProQR Therapeutics N.V.

ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10

Des améliorations rapides, significatives et durables de la vision à douze mois ont été rapportéesAmélioration concordante des mesures des résultats secondaires clésLa dose d'enregistrement cible du...
10 oct. 2019 06h00 HE | Source: ProQR Therapeutics N.V.

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...
07 oct. 2019 07h00 HE | Source: ProQR Therapeutics N.V.

ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
30 sept. 2019 07h00 HE | Source: ProQR Therapeutics N.V.

ProQR to Present at Two Investor Conferences in October

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...

Page précédente